Investigational KW-0761 efficiently depletes immune system-suppressing Treg cells

In a phase Ia clinical trial, immune cells called Tregs, which can inhibit anticancer immune responses, were efficiently eliminated from the blood of patients with lung or esophageal cancer by treatment with the investigational therapeutic antibody KW-0761. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail